Ernexa Therapeutics (ERNAW) Equity Ratio (2010 - 2026)

Ernexa Therapeutics has reported Equity Ratio for 17 years, with the latest figure at 0.65 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 155.32% year-over-year to 0.65; the trailing twelve-month figure through Mar 2026 stood at 0.65 (up 155.32% YoY), and the FY2025 full-year result was 0.41, up 27.48% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.65, up from 0.41 in the prior quarter.
• The five-year high for Equity Ratio was 0.65 in Q1 2026, with the low at 5.88 in Q3 2024.
• Historically, Equity Ratio has averaged 0.12 across 5 years, with a median of 0.41 in 2025.
• The largest YoY upside for Equity Ratio was 610.32% in 2024 against a maximum downside of 8727.0% in 2024.
• Ernexa Therapeutics' Equity Ratio stood at 0.54 in 2022, then tumbled by 91.64% to 0.05 in 2023, then jumped by 610.32% to 0.32 in 2024, then advanced by 27.48% to 0.41 in 2025, then surged by 58.08% to 0.65 in 2026.
• The last three Equity Ratio figures came in at 0.65 (Q1 2026), 0.41 (Q4 2025), and 0.58 (Q3 2025), per Business Quant data.